Drug intelligence / Profile preview

NBI-1065890

Development stage: Phase 2
Lead developer: Neurocrine Biosciences
Modality: Small Molecules
Administration: Oral

Overview

NBI-1065890 is an investigational, orally administered, selective small molecule inhibitor of vesicular monoamine transporter 2 (VMAT2). It is being developed by Neurocrine Biosciences as a next-generation VMAT2 inhibitor for the potential treatment of neurological and neuropsychiatric disorders, including psychiatric disorders such as schizophrenia. VMAT2 inhibitors work by modulating presynaptic dopamine storage and release, which has been clinically validated in the treatment of hyperkinetic movement disorders. The compound is currently in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adults[1][4][5][10].

Targets

VMAT2 (Vesicular monoamine transporter 2)

Beyond the preview

Go deeper on NBI-1065890.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NBI-1065890.

Explore the full profile